US2020188313A1PendingUtilityA1

Low dose topiramate/phentermine composition and methods of use thereof

73
Assignee: VIVUS INCPriority: Jun 9, 2008Filed: Feb 20, 2020Published: Jun 18, 2020
Est. expiryJun 9, 2028(~1.9 yrs left)· nominal 20-yr term from priority
A61K 31/35A61K 9/5026A61P 3/10A61P 11/06A61P 25/00A61K 31/7048A61K 31/357A61K 9/5047A61K 31/137A61P 3/06A61K 9/28A61P 25/06A61K 9/5015A61P 3/04A61P 11/00A61P 9/12A61P 3/00A61K 9/4808
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.

Claims

exact text as granted — not AI-modified
1 . A controlled release composition for treating obesity, diabetes, sleep apnea, or a related condition in a subject comprising:
 an effective amount of topiramate and phentermine.   
     
     
         2 . A method for effecting weight loss in a subject, comprising administering to the subject continually over a significant period of time a daily dose of phentermine in combination therewith a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.